Motilent and IBDrelief to define and deliver a new standard for IBD care.

[London, UK, 5th February 2025] IBD is a chronic condition of the gastrointestinal tract which includes Crohn’s disease and ulcerative colitis. The incidence of IBD is increasing globally.  It affects 10 million people and represents a growing burden on healthcare systems. IBD is treated with powerful and expensive medication which, in over 60% of cases, loses effectiveness within one year. Many patients require surgery to manage their condition.

Motilent’s technology platform, Entrolytics®, provides multi-modality viewing, enabling precision medicine in IBD and supporting over 500 projects globally in research, drug development and clinical practice, with CE marked and FDA cleared technology.

IBDrelief has developed multiple projects to support individuals living with IBD, helping them build knowledge, confidence and skills to improve their health and quality of life. Their flagship product, IBDmate, provides prescribable education covering a wide range of information, from topics on disease management like fundamentals, treatments, and procedures, to topics on managing quality of life in education, work, and relationships.

Recognising the urgent need to improve outcomes for people living with IBD, Motilent & IBDrelief aim to deliver an unparalleled standard of care by combining their complementary strengths in precision medicine and patient-centric support.

Alex Menys, CEO Motilent:

“Motilent and IBDrelief stand at different ends of the same problem. Motilent makes technology for precision care in IBD and our main job has been creating enabling technologies for precision care. IBDrelief comes from the patient side, leading by example and more recently creating powerful and impactful educational materials to help guide patients through their care.

“The pieces of the puzzle needed to deliver spectacular outcomes in IBD are out and on the table today. We have a dizzying array of advanced therapies. We now have ingestible cameras that can be used at home to survey the entire GI tract and ultrasound scanners that plug into a tablet. The majority of people have smartphones where they can upload all kinds of data from symptoms, diet and heart rate variability. We really have no good reason to explain why outcomes of IBD patients have flatlined over the past decade while getting more expensive, but they have - and this is wrong and it’s what Motilent and IBDrelief are committed to solving.

“We’re now bringing the technology and education together as we push for the changes that need to happen to improve outcomes in IBD patients and beyond. Think about where diabetes care is now and where it was 20 years ago. This is our vision.”

Seb Tucknott, co-founder IBDrelief:

“Historically, IBDrelief has been a small but passionate team dedicated to driving impactful change in IBD, empowering patients to take an active role in their care and self-management.

“Over the past 4 years paediatric IBD patients at Addenbrooke’s hospital in Cambridge have been using IBDmate, where 86% of parents and carers agree that IBDmate helped them or their child make more informed decisions around their care. This is exciting but is just the first step in understanding the benefits of patient education. To grow its impact we now urgently need to scale IBDmate into more centres across the UK.

“Joining Motilent marks the beginning of an exciting new chapter for IBDrelief, where we can leverage joint expertise and experience to achieve our goals. Additionally, by harnessing our unique patient insights, we are well-positioned to support and complement Motilent's vital work in advancing IBD care.”